Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes
Authors:
Open Access
- 23 December 2022
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 14, 3527-3538
Abstract
Acute myeloid leukemia (AML) is predominantly a disease of the elderly, and a significant proportion of these patients are not candidates for intensive, curative-intent therapies. Epigenetic dysregulation resulting in abnormal DNA hypermethylation is one of the hallmarks of AML pathogenesis. For the past two decades, hypomethylating agents including azacitidine (AZA) have been the mainstay of treatment for AML patients who are ineligible to receive intensive chemotherapies. As our understanding of AML disease biology has improved, several novel treatment combinations have been developed to improve the outcome of AML patients, with remarkable success. A considerable proportion of these novel combinations have utilized AZA as the backbone of their treatment scheme. In this review, we have highlighted the evolution of AML treatment, focusing on novel AZA-based treatment combinations and their clinical efficacy.Keywords
This publication has 66 references indexed in Scilit:
- AzacitidineDrugs, 2012
- Dose Escalation of Lenalidomide in Relapsed or Refractory Acute LeukemiasJournal of Clinical Oncology, 2010
- A phase I biological study of azacitidine (VidazaTM) to determine the optimal dose to inhibit DNA methylationEpigenetics, 2010
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemiaCancer, 2008
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaCancer Cell, 2006
- Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BJournal of Clinical Oncology, 2006
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidBlood, 2004
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002